Astrazeneca | search
Click here to view Astrazeneca news from 60+ newspapers.
Bookmark or Share- AstraZeneca’s Tagrisso gains EC approval for NSCLC treatmentAstraZeneca has gained approval from the European Commission (EC) for its oral therapy, Tagrisso (osimertinib), to treat adults with locally advanced, unresectable non-small cell lung cancer (NSCLC).. This approval in the European Union (EU) is specifically for cases where tumours exhibit epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations, and ...
- AstraZeneca withdraws application for lung cancer drug in EUAstraZeneca has voluntarily withdrawn its marketing authorisation application with the EU's medicines regulator for its experimental precision drug for the treatment of a type of lung cancer, it ...
- Tagrisso approved in the EU for patients with unresectable EGFR-mutated ...AstraZeneca’s Tagrisso (osimertinib) has been approved in the European Union (EU) for the treatment of adult patients with locally advanced, unresectable non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations and whose disease has not progressed during or following platinum-based chemoradiation ...
- Oxford–AstraZeneca COVID-19 vaccine - WikipediaThe Oxford–AstraZeneca COVID‑19 vaccine, sold under the brand names Covishield [31] and Vaxzevria [1] [32] among others, is a viral vector vaccine for the prevention of COVID-19.
- AstraZeneca - WikipediaAstraZeneca develops, manufactures and sells pharmaceutical and biotechnology products to treat disorders in the oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory and inflammation areas.
More
